Our data suggest that more potent CETP inhibitors, such as anacetrapib, that lower LDL-C (in addition to raising HDL-C) (Bloomfield et al. 2009) are likely to reduce CAD risk without any consequence on glycemic status. Here, CETP is linked to coronary artery disorder.